TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Recruiting · NCT06485466 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | Apatinib; Camrelizumab; Transarterial Chemoembolization; Unresectable Hepatocellular Carcinoma | Recruiting | Phase 3 | 2026-04-14 | NCT06485466 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guohui Xu | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sichuan Cancer Hospital and Research Institute | Chengdu | China | 7 |